Health Score

0 Poor

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Deposit reference lists for 80 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

High impact80 DOIs

Add license metadata to 80 records

License metadata tells indexers and readers how each article may be reused.

High impact80 DOIs

Attach ORCID iDs across 21 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact21 DOIs

DOIs for this ISSN

Showing the top 5 of 67 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	Clinical application of HALP score in the determination of n… (10.59854/dhrrh.2023.1.2.51)	References License	23.86	2
2	The Experience of Timisoara Hematology Clinic on the Managem… (10.59854/dhrrh.2024.2.2.65)	References License	15.05	1
3	Quantitative BCR::ABL1 Assay Using Digital Real-Time PCR Sys… (10.59854/dhrrh.2024.2.2.81)	References License	15.05	1
4	Diagnosis and Management of Essential Thrombocythemia: A Com… (10.59854/dhrrh.2024.2.3.125)	References License	15.05	1
5	Myelomatous Meningitis - a diagnostic and therapeutic challe… (10.59854/dhrrh.2023.1.1.13)	References License	0.00	0
6	COVID-19 infection in a patient with Follicular non-Hodgkin… (10.59854/dhrrh.2023.1.1.19)	References ORCID License	0.00	0
7	Philadelphia chromosome positive de novo AML or blast phase… (10.59854/dhrrh.2023.1.1.25)	References License	0.00	0
8	Cold Agglutinin Disease – Diagnostic and Therapeutic Challen… (10.59854/dhrrh.2023.1.1.7)	References License	0.00	0
9	The importance of MIR-4328 gene mutations in Acute Promyeloc… (10.59854/dhrrh.2023.1.2.37)	References License	0.00	0
10	Prognostic Significance of the Number of Copy Numbervariatio… (10.59854/dhrrh.2023.1.2.43)	References License	0.00	0
11	Investigation of Molecular Mechanisms Involved in Hepatitis… (10.59854/dhrrh.2023.1.2.59)	References License	0.00	0
12	Natural Killer cells at war: Unravelling the role of NK cell… (10.59854/dhrrh.2023.1.2.65)	References License	0.00	0
13	Lenalidomide and Carfilzomib in Relapsed and Refractory T Fo… (10.59854/dhrrh.2023.1.2.73)	References License	0.00	0
14	Identification Of Tet2 Gene Level Of Expression In Acute Leu… (10.59854/dhrrh.2023.1.4.185)	References License	0.00	0
15	Plasmablastic Lymphoma: The 'Rare' Frequency Among Immunocom… (10.59854/dhrrh.2023.1.4.191)	References ORCID License	0.00	0
16	Outcomes of allogeneic stem cell transplantation in acute le… (10.59854/dhrrh.2023.1.4.199)	References ORCID License	0.00	0
17	Acute Lymphoblastic Leukemia to Acute Promyelocytic Leukemia… (10.59854/dhrrh.2023.1.4.207)	References License	0.00	0
18	Allogeneic Stem Cell Transplantation in Treatment of Refract… (10.59854/dhrrh.2024.2.1.13)	References License	0.00	0
19	Checkpoint Inhibitors Prior to Autologous Stem Cell Transpla… (10.59854/dhrrh.2024.2.1.21)	References License	0.00	0
20	Multiple Myeloma and Solid Tumors – a Frequent Rarity – (10.59854/dhrrh.2024.2.1.27)	References License	0.00	0
21	Chronic Myeloid Leukemia Presenting with Megakaryocytic Blas… (10.59854/dhrrh.2024.2.1.31)	References License	0.00	0
22	A Rare Case of Immunotactoid Glomerulopathy Associated with… (10.59854/dhrrh.2024.2.1.41)	References License	0.00	0
23	Overview of ADAMTS13 Protein in Diagnosis and Patient Manage… (10.59854/dhrrh.2024.2.1.5)	References License	0.00	0
24	Cutaneous Complications after Autologous Stem Cell Transplan… (10.59854/dhrrh.2024.2.2.103)	References License	0.00	0
25	Real-Life Data, a Retrospective Report from Romania Hodgkin’… (10.59854/dhrrh.2024.2.2.51)	References License	0.00	0
26	Enhancing Multiple Myeloma Treatment Outcomes with Ixazomib:… (10.59854/dhrrh.2024.2.2.75)	References License	0.00	0
27	Real-World Treatment Patterns and Clinical Outcomes in Unfit… (10.59854/dhrrh.2024.2.2.87)	References License	0.00	0
28	Single Center Study Regarding Subucutaneous Immunoglobulins… (10.59854/dhrrh.2024.2.3.117)	References License	0.00	0
29	Prevalence and Impact of Hepatitis B and C in Hematological… (10.59854/dhrrh.2024.2.3.135)	References License	0.00	0
30	Thrombosis and Hemorrhage in Primary Immune Thrombocytopenic… (10.59854/dhrrh.2024.2.3.143)	References License	0.00	0
31	Chronic Neutrophilic Leukemia Developing in a Patient with M… (10.59854/dhrrh.2024.2.3.149)	References License	0.00	0
32	Dual Hemostatic Disruption in Light Chain Amyloidosis: A Com… (10.59854/dhrrh.2024.2.4.159)	References License	0.00	0
33	Study of Haemolytic Disease of the Foetus and Newborn with P… (10.59854/dhrrh.2024.2.4.167)	References ORCID License	0.00	0
34	The Impact of Current Treatment on The Symptomatology and Co… (10.59854/dhrrh.2024.2.4.177)	References ORCID License	0.00	0
35	Chronic Myeloid Leukemia: From the Classical Presentation To… (10.59854/dhrrh.2024.2.4.183)	References License	0.00	0
36	Real-World Outcomes of Patients Diagnosed with Philadelphia-… (10.59854/dhrrh.2024.2.4.189)	References License	0.00	0
37	IgA Myeloma at Diagnosis – Clinical, Paraclinical Characteri… (10.59854/dhrrh.2024.2.4.201)	References ORCID License	0.00	0
38	17p13.1 Deletion in Small B-cell Lymphocytic Lymphomas: A Pr… (10.59854/dhrrh.2025.3.1.11)	References License	0.00	0
39	Antiphospholipid Antibodies in Non-Hodgkin's Lymphoma (10.59854/dhrrh.2025.3.1.19)	References License	0.00	0
40	Is Quality of Life Better in Hemophilia Patients with or Wit… (10.59854/dhrrh.2025.3.1.29)	References License	0.00	0
41	Evaluation of the Benefit of Ropeginterferon Treatment in Pa… (10.59854/dhrrh.2025.3.1.39)	References License	0.00	0
42	Caplacizumab in the Treatment of Patients with Recurrent Thr… (10.59854/dhrrh.2025.3.1.49)	References License	0.00	0
43	DRD vs. D-VCD in Newly Diagnosed AL Amyloidosis: A Retrospec… (10.59854/dhrrh.2025.3.1.5)	References License	0.00	0
44	A Rare Case of Primary Pituitary Diffuse Large B-Cell Lympho… (10.59854/dhrrh.2025.3.2.101)	References License	0.00	0
45	Tacrolimus-Induced Diabetic Ketoacidosis (DKA) in Post Bone… (10.59854/dhrrh.2025.3.2.107)	References License	0.00	0
46	Clinical Diversity and Treatment Outcomes in IgM Monoclonal… (10.59854/dhrrh.2025.3.2.61)	References License	0.00	0
47	The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors… (10.59854/dhrrh.2025.3.2.67)	References License	0.00	0
48	A Retrospective Analysis of CLL Patients in a Romanian Hemat… (10.59854/dhrrh.2025.3.2.73)	References ORCID License	0.00	0
49	Prognostic Significance of Neutrophil to Lymphocyte Ratio in… (10.59854/dhrrh.2025.3.2.81)	References License	0.00	0
50	Hypercoagulability and COVID-19 Infection (10.59854/dhrrh.2025.3.2.89)	References ORCID License	0.00	0